Next Article in Journal
The Arabidopsis GPR1 Gene Negatively Affects Pollen Germination, Pollen Tube Growth, and Gametophyte Senescence
Next Article in Special Issue
Pro and Contra: Provocation Tests in Drug Hypersensitivity
Previous Article in Journal
Sexually Transmitted Infections: A Novel Screening Strategy for Improving Women’s Health in Vulnerable Populations
Previous Article in Special Issue
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): An Interplay among Drugs, Viruses, and Immune System
Article Menu
Issue 6 (June) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2017, 18(6), 1316;

Drug Hypersensitivity and Desensitizations: Mechanisms and New Approaches

Division of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
Department of Allergy, Marqués de Valdecilla University Hospital-IDIVAL, 39011 Santander, Spain
Department of Medicine, College of Medicine, King Saud University, Riyadh 12372, Saudi Arabia
Master of Medical Sciences in Immunology Program, Harvard Medical School, Boston, MA 02115, USA
Author to whom correspondence should be addressed.
Received: 2 May 2017 / Revised: 13 June 2017 / Accepted: 14 June 2017 / Published: 20 June 2017
(This article belongs to the Special Issue Drug Hypersensitivity)
Full-Text   |   PDF [2972 KB, uploaded 24 July 2017]   |  


Drug hypersensitivity reactions (HSRs) are increasing in the 21st Century with the ever expanding availability of new therapeutic agents. Patients with cancer, chronic inflammatory diseases, cystic fibrosis, or diabetes can become allergic to their first line therapy after repeated exposures or through cross reactivity with environmental allergens. Avoidance of the offending allergenic drug may impact disease management, quality of life, and life expectancy. Precision medicine provides new tools for the understanding and management of hypersensitivity reactions (HSRs), as well as a personalized treatment approach for IgE (Immunoglobuline E) and non-IgE mediated HSRs with drug desensitization (DS). DS induces a temporary hyporesponsive state by incremental escalation of sub-optimal doses of the offending drug. In vitro models have shown evidence that IgE desensitization is an antigen-specific process which blocks calcium flux, impacts antigen/IgE/FcεRI complex internalization and prevents the acute and late phase reactions as well as mast cell mediator release. Through a “bench to bedside” approach, in vitro desensitization models help elucidate the molecular pathways involved in DS, providing new insights to improved desensitization protocols for all patients. The aim of this review is to summarize up to date information on the drug HSRs, the IgE mediated mechanisms of desensitization, and their clinical applications. View Full-Text
Keywords: drug hypersensitivity; desensitization; precision medicine; mast cells; desensitization models; high affinity IgE Fcε receptor I; IgE drug hypersensitivity; desensitization; precision medicine; mast cells; desensitization models; high affinity IgE Fcε receptor I; IgE

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

de las Vecillas Sánchez, L.; Alenazy, L.A.; Garcia-Neuer, M.; Castells, M.C. Drug Hypersensitivity and Desensitizations: Mechanisms and New Approaches. Int. J. Mol. Sci. 2017, 18, 1316.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top